Trial Radar
Sign in

NCT lookup

Pull any trial record directly from ClinicalTrials.gov.

LYT-100 in Post-acute COVID-19 Respiratory Disease
LYT-100 in Post-acute COVID-19 Respiratory Disease

NCT04652518

TerminatedPhase 2

Sponsor: PureTech

Conditions: Covid19, Post-acute COVID-19 Respiratory Disease

Interventions: LYT-100, Placebo

Countries: United States, Argentina, Brazil, Moldova, Philippines, Romania, Ukraine, United Kingdom

This study is being conducted in two parts, A and B. Part A is a randomized, double-blind, parallel arm study to evaluate the safety and efficacy of LYT-100 compared to placebo in adults with post-acute COVID-19 respiratory complications. Part B is an Open Label Extension (OLE) study for patients who complete Part A.

Eligibility overview

Sex: ALL

Age: 18 Years to 80 Years

Healthy volunteers: No

Study type: INTERVENTIONAL

Eligibility criteria
Key Inclusion Criteria:

* Positive result of a molecular RT-qPCR diagnostic test or SARS-CoV-2 RNA result from a clinical specimen deemed clinically associated with the current episode of illness, warranting hospital admission as per investigator's judgement, or previously hospitalized (central and/or local laboratory COVID-19 test results are accepted from any biological material source)
* Hospitalization for COVID-19 respiratory disease and treated with supplemental oxygen (including MV, ECMO or any other means of oxygen administration) in hospital for at least 1 day
* COVID-19 pneumonia findings on imaging (chest X-ray or CT Scan) with a minimum of two lung lobes involvement
* Able to bear weight and ambulate a minimum of 10 m distance (use of inhaled oxygen permitted)
* Shortness of breath ≥ grade 3 on mBDS dyspnea scale and not requiring MV, ECMO, NIV, and/or HFNO (nasal O2 is allowed) for at least 72 hours before screening

Key Exclusion Criteria:

* Pre-existing chronic respiratory condition(s), obstructive or restrictive, for which the patient is actively taking concomitant medication are excluded. Patients with history of Idiopathic Pulmonary Fibrosis (IPF), lung cancer, pulmonary arterial hypertension, other interstitial lung diseases, severe cardiac insufficiency (grade IV) are excluded irrespective of whether they are actively being medicated for those conditions or not.
* Pre-existing co-morbid conditions preventing outcome assessments, e.g., neurological, medical, orthopedic injury/disability, disease or condition that would prevent ability to transfer and walk for 6 minutes, prior to confirmed COVID-19 diagnosis
* Unstable angina or myocardial infarction in the last month prior to screening
* Patients on MV, ECMO, NIV, and/or HFNO within the last 72 hours prior to screening
Locations (31)
  • Birmingham, Alabama, United States
  • Florence, Alabama, United States
  • Los Angeles, California, United States
  • Miami, Florida, United States
  • Orlando, Florida, United States
  • St. Petersburg, Florida, United States
  • Tampa, Florida, United States
  • Gainesville, Georgia, United States
  • Evergreen Park, Illinois, United States
  • Middletown, New York, United States
  • Winston-Salem, North Carolina, United States
  • Pittsburgh, Pennsylvania, United States
  • Nashville, Tennessee, United States
  • Houston, Texas, United States
  • San Antonio, Texas, United States
  • Villa Regina, Río Negro Province, Argentina
  • Rosario, Santa Fe Province, Argentina
  • San Miguel de Tucumán, Tucumán Province, Argentina
  • Curitiba, Paraná, Brazil
  • Porto Alegre, Rio Grande do Sul, Brazil
  • Rio de Janeiro, Brazil
  • Chisinau, Moldova
  • Manila, Philippines
  • Quezon City, Philippines
  • Bucharest, Romania
  • Cluj-Napoca, Romania
  • Craiova, Romania
  • Timișoara, Romania
  • Kiev, Ukraine
  • London, United Kingdom
  • + 1 more on CT.gov